Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Wang SH, Chi CC, Hu S. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. International Journal of Dermatology 2014; 53(9): 1151-1156 Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Biological Products /economics /therapeutic use; Cost-Benefit Analysis; Etanercept; Humans; Immunoglobulin G /economics /therapeutic use; Psoriasis /drug therapy /economics; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor /therapeutic use; Severity of Illness Index; Taiwan; Ustekinumab AccessionNumber 22014035831 Date bibliographic record published 19/11/2014 |